Jim Wassil Sells 3,477 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 3,477 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39. Following the completion of the sale, the chief operating officer owned 155,041 shares in the company, valued at $9,468,353.87. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total transaction of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total transaction of $126,742.50.

Vaxcyte Stock Performance

Vaxcyte stock opened at $61.17 on Friday. Vaxcyte, Inc. has a fifty-two week low of $30.81 and a fifty-two week high of $65.00. The stock has a market cap of $9.10 billion, a P/E ratio of -8.02 and a beta of 1.22. The firm’s fifty day moving average price is $58.13 and its 200-day moving average price is $56.17.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period in the prior year, the business posted ($1.22) EPS. Sell-side analysts predict that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds have recently added to or reduced their stakes in the company. Jupiter Topco LLC purchased a new position in shares of Vaxcyte in the 2nd quarter worth about $1,044,355,000. BlackRock Inc. bought a new stake in Vaxcyte in the 2nd quarter worth approximately $701,520,000. California State Teachers Retirement System lifted its position in Vaxcyte by 5,915.2% in the 2nd quarter. California State Teachers Retirement System now owns 8,186,622 shares of the company’s stock worth $475,888,000 after buying an additional 8,050,522 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Vaxcyte by 23.8% in the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after buying an additional 3,188,687 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its stake in Vaxcyte by 35.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock worth $521,213,000 after buying an additional 2,981,038 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on PCVX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.